Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Cellectar Biosciences, Inc. - Common Stock (NQ:CLRB)

0.3608 -0.0492 (-12.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Synergy CHC Corp. (NASDAQ: SNYR) Restructures Debt with $20M Facility to Power Global Growth and FOCUSfactor Beverage Expansion
Via AB Newswire
Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Announces Plan to Explore Strategic Alternatives
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences to Present at the 37th Annual Roth Conference
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer
Cellectar broadens global manufacturing network in preparation for potential commercialization of Iopofosine I 131 in 2025 
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences Inc. (NASDAQ: CLRB) Near Top of Volume Charts in Tuesday Trading
Via Investor Brand Network
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.